Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 3 Randomized Double-Blind Multinational Placebo-Controlled Study to Evaluate Efficacy and Safety of Teplizumab, a Humanized Fc Receptor (FcR) Non-Binding Anti-cluster of Differentiation 3 (CD3) Monoclonal Antibody, in Children and Adolescents With Newly Diagnosed Type 1 Diabetes

NCT03875729 is registered in ClinicalTrials.gov with Provention Bio, Inc. as lead sponsor.

NCT NCT03875729
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03875729 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 3 Randomized Double-Blind Multinational Placebo-Controlled Study to Evaluate Efficacy and Safety of Teplizumab, a Humanized Fc Receptor (FcR) Non-Binding Anti-cluster of Differentiation 3 (CD3) Monoclonal Antibody, in Children and Adolescents With Newly Diagnosed Type 1 Diabetes
Lead sponsor
Provention Bio, Inc.
Phase
Phase 3
Overall status
Completed
Start date
April 5, 2019
Completion date
May 1, 2023
Enrollment
328 (actual)
Sites
62

Conditions

As the registry lists them; a condition with its own page is linked.

type 1 diabetes mellitus